LRMR logo

LARIMAR THERAPEUTICS INC

LRMRNASDAQ
🏆 #3311 by market capUS Equity
$3.14▼ $0.03 (−1.10%)
After hours · at close
🔔
Track LRMR
Get earnings, price moves & breaking news on Telegram
Track
24h▼ 1.1%
7d—
14d—
30d—
ytd—
1y—
🏦Market Cap
$326M
Small Cap
📈Revenue Growth (YoY)
+0.0%
Slowing
📊Gross Margin
0.0%
Thin
💵FCF Margin
0.0%
Thin
⚖️P/S Ratio
0.0x
Cheap
Otter Score
52
Weak
No chart data available for LRMR.

Trading Snapshot

Day Range
$3.12 – $3.20
52-Week Range
$2.72 – $6.42
Volume
$4.18B
Avg Volume
$3.58B
Shares Outstanding
103.9M
Next Earnings
Nov 26, 2026

Fundamentals Snapshot

Annual Revenue
$47M
Last Q Revenue
$13M
P/E Ratio
-1.6
P/S Ratio
0.0x
EPS (TTM)
$-1.66
Dividend Yield
0.00%
Dilution (1yr)
+33.5%

Why Investors Own LRMR

  • ✓High-growth profile — revenue up +6.9% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 77% gross margin and 24% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

LRMR logo

LARIMAR THERAPEUTICS INC

LRMR
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$172M▲ +89.8% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$113M▲ +59.0% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
85.2M▲ +33.5% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$81M▲ +$53M YoY
StockOtter · stockotter.space

About LARIMAR THERAPEUTICS INC

Headquartered in Bala Cynwyd, Pennsylvania, Larimar Therapeutics, Inc. operates as a clinical-stage biotechnology firm. Its core mission involves crafting therapies for rare diseases, leveraging a distinctive cell-penetrating peptide technology platform. The company's foremost experimental therapy, CTI-1601, is presently undergoing Phase 1 clinical trials. This drug candidate is being developed to combat Friedreich's ataxia, a genetic illness that is rare, relentlessly progressive, and ultimately fatal.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Weak
52/100

Analyst Price Target

ⓘ
Average Target
$3.97
▲ +26.5% Upside
High Target$4.96
Low Target$3.42
Based on 22 analysts

Latest News & Updates

🚀
CNBC·2h ago

LARIMAR THERAPEUTICS INC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
Bloomberg·5h ago

Analysts lift LRMR price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
Barron’s·1d ago

LARIMAR THERAPEUTICS INC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.